What Factors are Fueling the Growth of the Vagus Nerve Stimulator Market?

Vagus Nerve Stimulator Market to Reach USD 1301.61 Million by 2032, Driven by Non-Invasive Neurostimulation Innovations The global Vagus Nerve Stimulator Market was valued at USD 552.74 Million in 2024 and is projected to reach nearly USD 1301.61 Million by 2032, growing at a CAGR of 11.3% during the forecast period. The market growth is being accelerated by the increasing prevalence of neurological disorders, rising demand for non-pharmaceutical therapies, and rapid advancements in non-invasive neurostimulation technologies. Rising Neurological Disorders Fueling Market Demand The growing global burden of neurological and psychiatric disorders such as epilepsy, depression, migraine, and chronic pain is significantly driving demand for vagus nerve stimulation (VNS) therapies. VNS devices are increasingly being adopted as effective alternatives for patients who do not adequately respond to conventional drug therapies. The rising incidence of treatment-resistant depression and drug-resistant epilepsy has encouraged healthcare providers to adopt advanced neuromodulation therapies that offer long-term symptom management and improved patient outcomes. Increasing awareness regarding mental health and neurological disorders, along with growing healthcare expenditure, is further contributing to market expansion worldwide. Non-Invasive VNS Devices Transforming the Industry Technological innovations are reshaping the Vagus Nerve Stimulator Market with the introduction of compact, wearable, and non-invasive stimulation devices. Non-invasive VNS (nVNS) devices, also known as transcutaneous vagus nerve stimulation (tVNS) systems, are gaining significant popularity due to their ability to provide therapy without surgical implantation. These devices reduce complications associated with surgeries while offering improved convenience and patient compliance. One of the major advancements in the market is the growing adoption of handheld devices such as gammaCore, developed by electroCore, Inc., which has received regulatory approvals for treating migraine and cluster headaches. Manufacturers are also focusing on AI-integrated and closed-loop neurostimulation systems capable of delivering personalized stimulation therapies and real-time monitoring, improving treatment precision and effectiveness. Implantable VNS Devices Continue to Dominate Based on product type, implantable VNS devices dominated the market in 2024 due to their widespread use in epilepsy and treatment-resistant depression therapies. These devices directly stimulate the vagus nerve through implanted electrodes, helping regulate abnormal brain activity and reducing seizure frequency and depressive symptoms. The growing number of FDA approvals for advanced implantable systems continues to support segment growth. For instance, the Vivistim Paired VNS System developed by MicroTransponder, Inc. has gained strong adoption for post-stroke rehabilitation therapies. Meanwhile, external VNS devic